It is the first ANDA product launched in the US market
Dr. Reddy’s Laboratories (DRL) recently launched Paricalcitol injection, USP, in 2 mcg, 5 mcg, 10 mcg. It is a therapeutic equivalent generic version of Zemplar (paricalcitol) Injection in the US market approved by the US Food & Drug Administration. It is the first ANDA product launched in the US market.
The Zemplar brand and generic had US sales of approximately $ 22.5 million MAT for the recent twelve months ending in July 2016 according to IMS Health.
EP News Bureau
- Advertisement -
Comments are closed.